Essential pathogenetic role for interferon (IFN-)γ in concanavalin A-induced T cell-dependent hepatitis:: Exacerbation by exogenous IFN-γ and prevention by IFN-γ receptor-immunoglobulin fusion protein

被引:45
作者
Nicoletti, F
Zaccone, P
Xiang, M
Magro, G
Di Mauro, M
Di Marco, R
Garotta, G
Meroni, P
机构
[1] Univ Milan, Inst Microbiol, I-20122 Milan, Italy
[2] Univ Catania, Inst Anatomopathol, Dept Microbiol & Gynecol Sci, I-95124 Catania, Italy
[3] Univ Catania, Inst Clin Med, I-95124 Catania, Italy
[4] Ares Serono, Geneva, Switzerland
[5] IRCCS, Hosp Auxolofico, Milan, Italy
关键词
D O I
10.1006/cyto.1999.0561
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
We have studied the effects of either exogenously-administered interferon (IFN-)gamma or of a nonimmunogenic mouse IFN-gamma receptor-Immunoglobulin (IFN-gamma R-Ig) fusion protein on the development of Concanavalin (Con)A-induced hepatitis in NMRI mice. PBS-treated control mice injected with 20 mg/kg ConA developed classical serological and histological signs of hepatitis with elevation of transaminases in the blood and infiltration of the liver by mononuclear cells and neutrophils. Treating the mice with rat IFN-gamma 24 h prior to and 1 h after ConA-challenge markedly exacerbated these signs of hepatitis in a dose-dependent fashion. Moreover, mice injected with lower, non hepatitogenic, doses of ConA (10, 5 mg/kg) became fully susceptible to develop hepatitis upon similar treatment with IFN-gamma. Concordantly, ConA-induced hepatitis was abrogated by either IFN-gamma R-Ig fusion protein or anti-IFN-gamma mAb, These data provide further evidence for the central pathogenetic role of endogenous IFN-gamma in ConA-induced hepatitis and demonstrate the feasibility to prevent disease development by means of a non immunogenic IFN-gamma R-Ig fusion protein, (C) 2000 Academic Press.
引用
收藏
页码:315 / 323
页数:9
相关论文
共 42 条
[1]   Immunomodulation of murine experimental SLE-like disease by interferon-γ [J].
Amital, H ;
Levi, Y ;
Blank, M ;
Barak, V ;
Langevirz, P ;
Afek, A ;
Nicoletti, F ;
Kopolovic, J ;
Gilburd, B ;
Meroni, PL ;
Shoenfeld, K ;
Shoenfeld, Y .
LUPUS, 1998, 7 (07) :445-454
[2]  
Billiau A, 1996, ADV IMMUNOL, V62, P61, DOI 10.1016/S0065-2776(08)60428-9
[3]   BIPHASIC EFFECT OF INTERFERON-GAMMA IN MURINE COLLAGEN-INDUCED ARTHRITIS [J].
BOISSIER, MC ;
CHIOCCHIA, G ;
BESSIS, N ;
HAJNAL, J ;
GAROTTA, G ;
NICOLETTI, F ;
FOURNIER, C .
EUROPEAN JOURNAL OF IMMUNOLOGY, 1995, 25 (05) :1184-1190
[4]  
CHATENOUD L, 1993, TRANSPLANT P, V25, P68
[5]   INTERFERON-GAMMA INHIBITS INTERLEUKIN-10 PRODUCTION BY MONOCYTES [J].
CHOMARAT, P ;
RISSOAN, MC ;
BANCHEREAU, J ;
MIOSSEC, P .
JOURNAL OF EXPERIMENTAL MEDICINE, 1993, 177 (02) :523-527
[6]   PURIFICATION AND BIOCHEMICAL-CHARACTERIZATION OF A SOLUBLE MOUSE INTERFERON-GAMMA RECEPTOR PRODUCED IN INSECT CELLS [J].
FOUNTOULAKIS, M ;
SCHLAEGER, EJ ;
GENTZ, R ;
JURANVILLE, JF ;
MANNEBERG, M ;
OZMEN, L ;
GAROTTA, G .
EUROPEAN JOURNAL OF BIOCHEMISTRY, 1991, 198 (02) :441-450
[7]  
GANTNER F, 1995, HEPATOLOGY, V21, P190, DOI 10.1002/hep.1840210131
[8]   Protective major histocompatibility complex genes and the role of interleukin-4 in collagen-induced arthritis [J].
Hesse, M ;
Bayrak, S ;
Mitchison, A .
EUROPEAN JOURNAL OF IMMUNOLOGY, 1996, 26 (12) :3234-3237
[9]   HUMANIZED MONOCLONAL-ANTIBODY THERAPY FOR RHEUMATOID-ARTHRITIS [J].
ISAACS, JD ;
WATTS, RA ;
HAZLEMAN, BL ;
HALE, G ;
KEOGAN, MT ;
COBBOLD, SP ;
WALDMANN, H .
LANCET, 1992, 340 (8822) :748-752
[10]  
Itoh M, 1998, CLIN EXP IMMUNOL, V111, P513